<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-032527
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051024
<FILING-DATE>20051025
<DATE-OF-FILING-DATE-CHANGE>20051024
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051153144
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v027630_6k.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
          AND EXCHANGE COMMISSION</strong></font></a></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
          D.C. 20549</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
          6-K</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
          OF
          FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
          to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
          Securities Exchange Act of 1934</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
          the month of October 2005</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
          File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
          Limited<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
          of registrant&#8217;s name into English) </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
          12
          BGC Centre<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
          The
          Esplanade<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
          WA
          6000<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
          of principal executive offices)</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
          by check mark whether the registrant files or will file annual reports
          under
          cover Form&#160;20-F or Form&#160;40-F). </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
          20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
          40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
          by check mark if the registrant is submitting the Form 6-K in paper as
          permitted
          by Regulation S-T Rule 101(b)(1):</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
          by check mark if the registrant is submitting the Form 6-K in paper as
          permitted
          by Regulation S-T Rule 101(b)(7):</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
          by check mark whether the registrant by furnishing the information contained
          in
          this Form is also thereby furnishing the information to the Commission
          pursuant
          to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
          "Yes"
          is marked, indicate below the file number assigned to the registrant in
          connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
          </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
          to the requirements of the Securities Exchange Act of 1934, the registrant,
          pSivida Limited, has duly caused this report to be signed on its behalf
          by the
          undersigned, thereunto duly authorized. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
          <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

              <tr valign="top" bgcolor="#ffffff">
                <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                  October 24, 2005</font></td>
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td>&#160;</td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                  Finlay</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
                <td align="left">
                  <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
                </td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td>
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                    Finlay</font></div>
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                    Financial Officer and Company
                    Secretary</em></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
          INDEX</u></em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div align="left">
          <table border="0" cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="10%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                    99.1:</strong></font></div>
                </td>
                <td align="left" valign="top" width="90%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                    to Present at Lux Executive Summit in Cambridge,
                    MA</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
          </div>
          <div id="PN">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v027630_ex99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%"><strong><font size="2">ASX/MEDIA
                RELEASE</font></strong><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></td>
              <td width="50%" align="right"><IMG SRC="logo.jpg">
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;<strong><font size="2">24
                  October
                  2005</font></strong></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      to present at Lux Executive Summit in <br>Cambridge,
      Massachusetts</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: #000000" align="center" noshade size="2" width="100%">
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
      bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      pleased to announce that CEO, Mr Gavin Rezos will present a corporate overview
      to potential investors at the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lux
      Executive Summit in Cambridge, Massachusetts today.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      summit will focus on the business impact of nanotechnology and is the premier
      forum for executives and investors in the nanotechnology industry.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Lux
      Executive Summit is presented by Lux Research, the only research firm focused
      exclusively on nanotechnology.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Focusing
      on the business impact of nanotechnology, the Lux Executive Summit will present
      exclusive ideas and data from Lux Research's renowned analysts. The summit
      is a
      meeting of business leaders who want to understand how nanotechnology will
      change products, commerce, and ultimately society.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited recently announced that it had entered into a definitive merger
      agreement to acquire Control Delivery Systems, a US based drug delivery company
      with the potential to create a global bio-nanotech company specializing in
      drug
      delivery, with revenues from existing products and generating long-term value
      through its diversified late-stage product portfolio</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is committed to the biomedical sector and the development of products in
      healthcare. The company&#8217;s focus is the development and commercialisation of a
      modified form of silicon (porosified or nano-structured silicon) known as
      BioSilicon&#8482;. As a new and exciting biocompatible material, BioSilicon&#8482; offers
      multiple potential applications across the high growth healthcare sector,
      including controlled release drug delivery, targeted cancer therapies (including
      brachytherapy and localized chemotherapy), tissue engineering and orthopaedics.
      Potential diagnostics applications are being developed through its subsidiary
      AION Diagnostics Limited. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
      animals. The IP portfolio consists of 29 patent families, 34 granted patents
      and
      over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
      biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information about Lux Research, please visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.luxexecutivesummit.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
      by:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 9 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
      Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      pSivida
      is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
      Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
      largest science and technology company in Europe. QinetiQ is the former UK
      government Defence Evaluation Research Agency and was instrumental in
      discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
      having access to its cutting edge research and development facilities. For
      more
      information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. Although we believe that the expectations reflected in such
      forward-looking statements are reasonable at this time, we can give no assurance
      that such expectations will prove to be correct. Given these uncertainties,
      readers are cautioned not to place undue reliance on such forward-looking
      statements. Actual results could differ materially from those anticipated in
      these forward-looking statements due to many important factors including: our
      failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues. Other reasons are contained in
      cautionary statements in the Registration Statement on Form 20-F filed with
      the
      U.S. Securities and Exchange Commission, including, without limitation, under
      Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any
      oral or
      written forward-looking statements that may be made by or on behalf of
      pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0HV17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C`T(#`T.C$T
M.C`T``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```#T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)"`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!!?M$;MSMKVOCZ6Y0<SG]C'[A
MCQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW58E#=SRV0SU++';*,:G<?Y[)
MMJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4M?\`S=EE'^']/^9?^BL_2*\_
M]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8`Y>/N2D)WQ1,>*'!'@^;_"3P
MV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8V7N.5U%X;D6;6?2=C_8:_P#C
M/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]VZQUOH[7N]7]+7O]*S^;4Z^E
M8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PBL]3ZCC],P+L_)W&G';N?L&YT
M2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K:27-._Q@_5YK\>3?Z61$Y'I$
M55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRFAEAI99J^T>$@<_R)W.3.9SQP
M8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;CD8KQ+G/=)_L?2_\`(*=GV;]K
M5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.0\/S_I8Y^J.1?P^-Z6WDEF=.
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M-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?Z+O^Y'I(S?V1T#IE=9?5@X&*
MT,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".(WH:KJYG4:<FBFFJX5!K2\L-
M0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1N+CI['/^C[O[2HYN7E=7%;\/
M'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F4MCIC6,Q6UM98Q[6M%AM#MQ,
M?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^XXN-DX_2*&W7_O6U76VMC6-X
M:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M
M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=YD787HX^+F-)-C6D.(@-,;=W
MJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGAWTLC&=^?[&;_`/3?X;U%UN3B
M493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/THR6<O$@\4M+C$:?U0Y=8LZ=
MU&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2U6<7IF)BO]2MI+^SG&2)_=17
M8E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F,>>.+BE..'%CEQ2A&<FP9"_I
M5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;]&E__75<R.G_`+._Q8.H(BQ]
M-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`9RXU[7N9]/;O:=A&YKMC59ZE
MT[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5.$WDU'J!$/\`#^9X+ZQ3_P"-
MKTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"VQ'YJZBSZO]+MZ,WHEE9?A,:U
MC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-N)8VZNYUCB\N:6NK:]T_S5>S
MV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*>L55;LGJF4T'TF%K?;7LBZUV
MRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@!HL<+<G?:VMI<UGJ.]VQ;O5/
MJ=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C]FS]&K'2?JYTGHU^1?T^HTG)
M@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3]"/W7__1[#ZT_8_MF)'[2_:.
MRST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_S2^WU>IZO[:@>G^U_5^U=X^S
M?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209GZJ27RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]G_[0[P4&AO=&]S:&]P(#,N,``X
M0DE-!"4``````!``````````````````````.$))30/M```````0`$@````!
M``$`2`````$``3A"24T$)@``````#@`````````````_@```.$))300-````
M```$````>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`
M.$))300*```````!```X0DE-)Q````````H``0`````````!.$))30/U````
M``!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!
M`%H````&```````!`#4````!`"T````&```````!.$))30/X``````!P``#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z`````#_________
M____________________`^@``#A"24T$`````````@`!.$))300"```````$
M`````#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````-)````!@``````````````/0```-@````*`%4`;@!T
M`&D`=`!L`&4`9``M`#$````!``````````````````````````$`````````
M`````-@````]``````````````````````$`````````````````````````
M$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<````]`````%)G:'1L;VYG````V`````9S;&EC97-6;$QS`````4]B
M:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G
M<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X`
M```-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E````
M`$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@
M;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````/0````!2
M9VAT;&]N9P```-@````#=7)L5$585`````$```````!N=6QL5$585`````$`
M``````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E
M;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO
M<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)
M=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=```
M``MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N
M90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``````
M```,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG````
M```X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````"20`
M```!````@````"0```&````V````"0@`&``!_]C_X``02D9)1@`!`@$`2`!(
M``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"
M$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!
M!?M$;MSMKVOCZ6Y0<SG]C'[ACQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW
M58E#=SRV0SU++';*,:G<?Y[)MJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4
MM?\`S=EE'^']/^9?^BL_2*\_]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8
M`Y>/N2D)WQ1,>*'!'@^;_"3PV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8
MV7N.5U%X;D6;6?2=C_8:_P#C/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]
MVZQUOH[7N]7]+7O]*S^;4Z^E8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PB
ML]3ZCC],P+L_)W&G';N?L&YT2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K
M:27-._Q@_5YK\>3?Z61$Y'I$55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRF
MAEAI99J^T>$@<_R)W.3.9SQP8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;C
MD8KQ+G/=)_L?2_\`(*=GV;]K5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.
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MSOH_]J;/4_06_HOTEGK5UF^L-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?
MZ+O^Y'I(S?V1T#IE=9?5@X&*T,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".
M(WH:KJYG4:<FBFFJX5!K2\L-0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1
MN+CI['/^C[O[2HYN7E=7%;\/'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F
M4MCIC6,Q6UM98Q[6M%AM#MQ,?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^
MXXN-DX_2*&W7_O6U76VMC6-X:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3
MCUONM?6`RNMI<YQW-^BQON<M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=
MYD787HX^+F-)-C6D.(@-,;=WJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGA
MWTLC&=^?[&;_`/3?X;U%UN3B493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/
MTHR6<O$@\4M+C$:?U0Y=8LZ=U&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2
MU6<7IF)BO]2MI+^SG&2)_=178E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F
M,>>.+BE..'%CEQ2A&<FP9"_I5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;
M]&E__75<R.G_`+._Q8.H(BQ]-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`
M9RXU[7N9]/;O:=A&YKMC59ZET[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5
M.$WDU'J!$/\`#^9X+ZQ3_P"-KTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"V
MQ'YJZBSZO]+MZ,WHEE9?A,:UC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-
MN)8VZNYUCB\N:6NK:]T_S5>SV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*
M>L55;LGJF4T'TF%K?;7LBZUVRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@
M!HL<+<G?:VMI<UGJ.]VQ;O5/J=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C
M]FS]&K'2?JYTGHU^1?T^HTG)@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3
M]"/W7__1[#ZT_8_MF)'[2_:.RST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_
MS2^WU>IZO[:@>G^U_5^U=X^S?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]DX
M0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N
M`#`````!`#A"24T$!@``````!P`!`````0$`_^$22&AT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E
M<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G
M('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU
M)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U
M=6ED.C9E,&(S86(W+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8R<*("!X
M;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^
M"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C9E
M,&(S86(U+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8SPO>&%P34TZ1&]C
M=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z
M>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_[@`.061O8F4`9(`````!
M_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``]`-@#`2(``A$!`Q$!_]T`!``._\0!/P```04!`0$!`0$`````````
M`P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$
M`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$
M`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U
M5)),3`)\$E+I*G7U3%>X-.ZLNT&]I:#\U8NOJHK]2UVU@TGXJ*',89QE..2)
MC'YC?R?WOW4T>R1)4_VM@?Z7\#_<A974R^HU]-?4_+>8K%VYK)/[VQKG)HYO
MEB0!FQDG0>N*B"!='[&WE9>+ATNR,JUM-+/I/>0!^*Q&]>ZIU4EO0<2,?C]H
M9DLJ/\JBD?IKDU?U?I:]O4/K)D_M#*:996X1CUG]VC&_._KO6SCYM%Q+*VN8
M&-F7-VM@*0YL49C&9Q]P[0OU?XK'626I]$?^=]OZ+S/6[OK1T2BC/?U)F8Y]
MS*G8GHM8UV\_1K<#ZBZX20"=#X+GZ:7]?ZM7U*P1TKI[C]A:?\-;]%^7_P`3
M7]''_P"W%T*D*,8UD03PGY;/%_A>I2222#(I))#=D8[3#K6-/@7`(2E&.LB(
M^9I21),US7"6D$'N-5&VUE3#98=K&\E(R`!D2!$"[Z5W4S20J,FC(!-+]X;H
M45",XSB)1(E$[2B>**E))(>1?5C469%SME532^QQ[-:-SBG*2)+/Z9U[I/57
MO9T_(%[J@'/`#A`/'TVM6@D@$$6""/!22A9;74PV6O;6P<N<0`/[3DU.1CW@
MFBUEH;H2QP='QVI)OHD22224I))))3__T/54DDDE.3U>L.+M)]L@^\Q']7]$
MK'3;Q9T\.N(BN0YSN(;^<Z?Y*;J51)#APX%O#S^%1VK&=TQ_5::^FW9#L;'9
M87Y5#?:ZYA`V5;OS6[Q^D61#]7\3/%48YHRC_>E_.0XOZZ^1/MV!Q$=&74+*
M;<DVXY:ZFQK7L<W@@CZ06MT9C/L37;1NW.UC7E974::J,GT*6AE53&,K8.`T
M-AK0M;I#FMZ>'.(#0723\54Y`1_TKS.@H>[]/UD5TK]N-[Z-+J#C?U+TW:LJ
M&C8<1Q)_F_<KXQ6Y6$RFPGTG_P`ZT%TN$_S9-GZ38[\]9@)OS+LAH.QQ(:8>
M0>W^"A;M+-E36=P`#S_W[W*Y\,N>?F,VA$Y2J7Z7#Q?J_P#!X8+<@'"`R:UK
M&AC`&M:(:T:``=@AY.5CXE#\C)L;536)?8XP`.-458?UU_\`$OG_`-1O_5L6
ML-V*9X8RD/T03]C<9U_HK\5^8W,J.-6[8^W<-H=&[9_63].Z[TCJA<W`RF7O
M9JY@,.`\=CMKEP/U%^K^!UIF4>H;[*L9S?3I#BUFYX.ZQVW\_P!BI8M7[$^N
M]>-C..RG*%0)Y-=D-V._L/3N$:CLU1S.3AQS,1P3/#OZGTKK.393CM96=KK#
M!(Y@<JAA=).50;C9MDD-$3Q^\M7J&&,NC8#M>TRP^?@L:N[.Z;86D%H/+':M
M/P7/?$8"/.C+S4)9.4,>&/#?#CEX\+HP^6HFI)NGLSL7+](,<ZO=MLCZ/]<+
M7RV4OQWMO=LK(]SIB-4'!ZE3E^WZ%HU+#W_JI^J?T"[X#\H5SEH8L7(Y3BR?
M>,7#.<1/Y8CA_FO^^6DDR%BBMTZK#J:\8MGJ`D;C,P5#'Z]T;*R1B8^959D$
MD"IKO=+?IZ?R4'H'\U=_6'Y%P756?L+Z]B]OMJ-[+Q_4M_G?^JL5GX;(9.5Q
MR$1CL&H0^6/JDP<SD.(@[@R$9$^+Z3G=2P.G5MLSKV8['G:USS`)YA!NR.F=
M2Z1?9Z[78%M;VV7L.@;!;8X/_DKB?\9V8;,[#P&&?38;2T?O6'8S_HL73W8(
MZ?\`4RW#`@TX3P[^L6.=9_TRKE:`]UGNF4\D:'#C'_.[(/JGTWZM85^0[HN8
M<JQ[&BT%X?#03M/M:Q;F=U'!Z?3Z^;<RBJ8#GF)/@W]Y<'_BM_IF?_Q5?_5.
M0/\`&7DVV=:HQI/ITTAS6]MSW.W._P"BU*KE3''/P<N,@B!K0B/EW>A^M75^
MF=4^JF<[!R&9`:&;FM/N'O9])CO<J7^*T`86?_QK/^I5?ZP_4[I73?JT<W'W
MMRZ6,]2S<2+-Q:UX>SZ.WW*S_BN_H6?_`,:S_J4=.$UW6@S/-8^,`'@/R[?I
M/79W4L#I]8LS<BO'8>"]P$_U1])RIXGUI^K^9:*:,ZIUCC#6DEI)_D^IM7-]
M7^I76>L=>?F9E]8PG/AH:XE[*1PUC2W9O6#]<NC=#Z7;CMZ5?O>[<+Z=XL+2
MV-C]/H;D``>J_)GRPXI<`$(FO4?5+^Z^KI+)^JN5=E_5[!OO=OL=4`YQY.TE
MDG_-20K6FQQC@X^G#Q/_T?55%[V5L=98X-8P%SG'0`#DE27*]=NNZ]U<?5O$
M>68E(%O5+F\[>68S3_+2"V<^$=R=(CO))@9O4?K%U/[7CO=C="Q2YC=(.4[Z
M+IG_``#5J6]$H>[<RQ[#VD[OR^Y7L?'IQJ&8]#!754T-8QN@`"(H<_+8,]>[
MC$ZV_>_QHIQ\4!\UDZR>7S:#CY+JB\V$`>X\ZA6\'I8RL<6.M<UI)&P<:%4^
MMY3&]4=CU`WY3@"W'KU=$?2?^;57_P`)8M3HN/<<9K\BQKH)VU5_0:9[O/NN
M=_+^@L+E/A\9<[F&3'^HO(,8D3'CX9_HZ\>2,66630")N6EU^CYMO%Z=1BG<
MTN<X<%QX^#?HJTDDN@Q8L>*(ACB(1'2*PDG=2Q/KK_XE\_\`J-_ZMBVUB?77
M_P`2^?\`U&_]6Q2#<,>7^;G_`'9?DX'^*W^8ZC_7J_(]8?4??_C`.W7]>K&G
MD62I?4_HF;U+'S+^G9K\',H<QK'-)#'-<'$MLV^[LM[ZM_4/+PNJ,ZEU2YEC
MZ7%]=;"7%SS_`(2RQX:GF@26C",\F+#`1T$N+CZ5;U>?GC##9K+]\P08&B?'
MNHZAC2]H,Z/8=8*)DXU>34:K.#J".0?%9+NB9;''TK&EI[R6F/.%D\S/G<><
MRCC^\\M.->T.$2A+_NG4CPD;T>[5(%'4-M!D,L`8?FMOJG]`N^`_*$#!Z.W'
ML%MSM[V_1`X!\5;S*'9&,^EI`+QH3QRH>2Y/-CY7FA*/!+.)G'A!O@],N$)E
M(&4?#JT>@?S5W]8?D7+_`.-#`]N'U%HX+J+#\?TE7_HQ=ATW!LPV/:]P=O((
MCR0/K)T<]9Z1=@M<UECMKJGNX#FG=V5[X9CGBY7%#(.&40>*/^%)@YJ'N0F!
MK>WF'SKI3K?K'];,1]PD#TS8#K[:&-W?Y[F?]->D_6#_`)"ZA_X6M_ZARQ/J
MC]3LCH69=EY5M=SWUBNOTP=).Y_TOZK5T/4\5^9T[*Q*R&OOJ?6USN`7-+9*
MN2(L5T8<&*<<4^(>N=DO"_XK?Z9G_P#%5_\`5.5+_&."WZQM<>/0K/W%ZZCZ
MG_5/,Z!?DVY-U=HO8UK17.A:2==WQ4_KA]47=>]+(QK&U9=(+/?.U["=VUQ;
M]':Y&QQ6Q>QD/*B%>L'BX?JS^N;FN^J&0YIEKF5$'Q!<Q97^*[^A9_\`QK/^
MI4*?J'UF_I[L?J742\5L+<3&#G&ICOS7V$Q]#]S8MKZG_5S*Z!CY-63:RTWO
M:YIKG0`;==R&E$6OC')+/#(8&($:>6ZAUGJWUJZ[^Q\&\XN$7N8T`D2UD^I=
M;M]S_H^VI5_KC]6NG=!Q<)F*YS[[G/\`6L>=7`!NWV#VL;JM+._Q>]5JZF[+
MZ/E,K87FRLN+F/K+C.W<QKMRGG?XN^IY=;+KNH_:,]Q/K67;BP-_-95])WTD
M;&FNC#+%EE'()8S+(3I,G01_J/1?4O\`\3&!_4/_`%;TE:^K_3KNE]'QL"YS
M7V4-+7.9,&7.=IN_K))O7ZMSA/L\->K@JO'A?__2]-SLVC!Q795YVU,+0YW8
M;G!DG_.5+HG26]-=G7FUMQSLAV1ZO?8[Z#''_@_<C];_`&=^R<K]I_T+TSZW
M,Q_)C\_=]!>=4#ZI;1N=U@XG8$`5Q\:W%$;,4^(3C41+]VY<)XOTGN^I_6SH
M?33LLR!=?PW'H_2/)_=VL^C_`&E2KL^M'73.T]#Z<[OH[*>/*?;CHGU;_P"9
MT#]B>AZL:S_/?/UOTRZ%+3HGAG+YY4/W8?MFXE7U=&-4:,1S:JW&;#JZRP_O
MY%SO?:Y6\/"S<7:P7,-0,ENW7S@K025'[KR_WCCXY?>*NO=E[G!_<XOYMEC+
MT`1`X.E#TJ2225U"EG]>Z:_JO2<G`K>*WWM#0]PD"'-=V_JK0221(`Q(EM6O
MD\]]4?JS?]7Z\EEU[+_M#F.!8"(VAP_._K+H4DD3=ZK<8@(`0UCTH\2DDDD%
AZDDDDE*22224I))))2DDDDE*22224I))))2DDDDE/__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
